Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

12.87 

0.03 0.2%

as of Aug 07 '20

52 Week Range:

9.74 27.82


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 3.06
5.02
4.54
4.03
3.87
2.17
2.62
growth rate 64.1% -9.6% -11.2% -4.0% -43.9% 20.7%
Earnings BIT -20.96
-0.80
-2.40
-55.05
-132.55
-111.83
-136.84
-128.11
-177.14
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -39.10
-39.10
-39.10
-39.10
-8.05
-8.05
-8.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -56.22
-1.00
-2.81
-30.37
-63.47
-46.86
-49.58
-43.77
-49.49
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -14.09
-41.58
-80.27
-59.38
-61.46
-52.79
-65.78
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -14.27
-41.62
-79.71
-59.88
-62.34
-54.71
-62.96
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 3.12
2.83
4.62
11.44
11.55
11.50
11.59
7.20
11.61
growth rate -9.3% 63.3% 147.6% 1.0% -0.4% 0.8% -37.9% 61.3%
Quick Ratio 3.10
2.81
4.55
11.27
11.30
11.22
11.23
6.90
11.18
growth rate -9.4% 61.9% 147.7% 0.3% -0.7% 0.1% -38.6% 62.0%
Leverage 1.56
1.24
1.29
1.25
1.23
1.18
1.45
growth rate -20.5% 4.0% -3.1% -1.6% -4.1% 22.9%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 1.87
1.80
33.70
2.08
0.26
0.32
0.63
20.75
3.51
growth rate -3.9% 1,772.2% -93.8% -87.4% 21.4% 98.4% 3,187.8% -83.1%
Acct.Payable 4.20
3.00
4.70
8.30
4.65
4.99
7.00
4.78
8.78
growth rate -28.5% 56.7% 76.6% -43.9% 7.3% 40.2% -31.7% 83.7%
Cur.Assets 35.42
100.60
159.70
195.01
213.06
248.67
285.80
272.54
399.18
growth rate 184.0% 58.8% 22.1% 9.3% 16.7% 14.9% -4.6% 46.5%
Total Assets 37.36
103.50
163.00
199.20
217.90
252.44
289.36
275.50
424.59
growth rate 177.0% 57.5% 22.2% 9.4% 15.9% 14.6% -4.8% 54.1%
Cash 33.34
98.00
123.60
190.10
208.32
77.90
226.66
86.67
139.48
growth rate 193.9% 26.1% 53.8% 9.6% -62.6% 191.0% -61.8% 60.9%
Cur.Liabilities 11.35
35.50
34.60
17.05
18.45
21.62
24.66
37.83
34.39
growth rate 212.8% -2.5% -50.7% 8.2% 17.2% 14.1% 53.4% -9.1%
Liabilities 34.26
154.60
58.70
38.92
48.37
50.74
53.99
42.49
93.45
growth rate 351.3% -62.0% -33.7% 24.3% 4.9% 6.4% -21.3% 119.9%
LT Debt 0.00
0.00
0.73
0.73
0.11
36.10
growth rate 0.0% -84.9% 589.8%
Equity 104.30
160.28
169.53
201.70
235.37
233.01
293.71
growth rate 53.7% 5.8% 19.0% 16.7% -1.0% 26.1%
Common Shares 22.00
22.00
17.00
33.00
40.00
57.00
61.00
72.00
90.00
growth rate 0.0% -22.7% 94.1% 21.2% 42.5% 7.0% 18.0% 25.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 0.92
1.48
0.63
2.22
0.18
0.62
0.98
0.30
0.59
growth rate 61.4% -57.5% 251.8% -91.7% 241.0% 57.7% -69.6% 98.7%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 10.00
44.20
-35.36
-72.93
-96.37
-120.43
-121.60
-147.17
growth rate 342.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -1.54
-1.00
-2.99
-1.84
-1.91
-1.87
-1.57
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 19.08
0.00
0.00
104.47
132.14
132.40
156.88
growth rate -100.0% 26.5% 0.2% 18.5%
FCF 9.00
43.00
-54.00
-38.00
-113.00
-97.00
-121.00
-122.00
-148.00
growth rate 377.8% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 6.94
45.20
68.50
41.41
2.56
8.01
10.00
21.70
23.80
growth rate 550.9% 51.6% -39.6% -93.8% 212.8% 24.9% 117.0% 9.7%
Op.Income -20.96
-0.70
-3.50
-55.05
-132.55
-111.83
-136.84
-128.11
-177.14
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -20.96
-1.50
-3.10
-54.90
-132.38
-110.21
-134.65
-123.57
-170.24
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -20.96
-0.70
-3.50
-55.01
-132.38
-110.21
-134.31
-123.63
-170.30
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -0.94
-0.05
-0.22
-1.67
-3.32
-1.93
-2.18
-1.72
-1.93
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 6.94
45.20
68.50
-34.18
-108.65
-83.45
-99.66
-84.13
-108.84
growth rate 550.9% 51.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
R&D 22.91
38.50
57.60
75.60
111.21
91.46
109.66
growth rate 68.0% 49.6% 31.2% 47.1% -17.8% 19.9%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT -50.71
-37.95
-57.49
-51.35
-57.57
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 13.27
12.00
3.51
1.65
1.75
growth rate -9.6% -70.8% -53.0% 5.9%
Acct.Payable 7.07
5.35
8.78
5.93
4.58
growth rate -24.3% 64.0% -32.5% -22.7%
Cur.Assets 358.36
320.94
399.18
402.44
354.66
growth rate -10.4% 24.4% 0.8% -11.9%
Total Assets 371.41
334.20
424.59
451.64
427.38
growth rate -10.0% 27.1% 6.4% -5.4%
Cash 45.93
93.46
139.48
179.26
117.15
growth rate 103.5% 49.2% 28.5% -34.7%
Inventory 1.70
growth rate
Cur.Liabilities 33.93
29.43
34.39
27.18
30.66
growth rate -13.3% 16.8% -21.0% 12.8%
Liabilities 45.73
40.46
93.45
111.32
growth rate -11.5% 131.0% 19.1%
LT Debt 36.10
61.47
growth rate 70.3%
Equity 288.25
256.31
293.71
304.19
growth rate -11.1% 14.6% 3.6%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 11.1% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 0.17
0.23
0.17
0.06
growth rate 37.9% -26.6% -63.2%
Cash From OA -41.89
-38.23
-35.48
-58.27
growth rate 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -42.06
-38.46
-35.66
-58.33
growth rate 0.0% 0.0% 0.0%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 5.90
5.72
4.29
1.35
growth rate -3.1% -24.9% -68.5%
Op.Income -50.71
-37.95
-57.49
-51.35
-57.57
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -48.47
-36.09
-56.34
-50.94
-58.45
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -48.47
-36.09
-56.40
-50.94
-58.45
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit -35.01
-20.86
-33.96
-24.42
growth rate 0.0% 0.0% 0.0%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (7.49)

YOY Growth Grade:

F (10.71)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -8.05 -6.31 -6.09
EPS / Growth 0.0% -2.04 38.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 8.1% 8.1%
Future PE 0.00 0.01 5.43
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.